Form 4: Dexcom Executive Sells Shares Under Pre-Arranged Trading Plan

Dexcom's EVP and Chief HR Officer, Sadie Stern, sold 1,466 shares of common stock for $88.99 per share under a Rule 10b5-1 trading plan.

Summary

• Sadie Stern, Executive Vice President and Chief HR Officer of Dexcom Inc. (DXCM), disposed of 1,466 shares of common stock.
• The transaction occurred on July 28, 2025, at a price of $88.99 per share.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Ms. Stern on February 20, 2025, designed for the orderly disposition of shares.
• Following this transaction, Ms. Stern beneficially owns 106,689 shares of Dexcom common stock.
• The remaining beneficial ownership includes 74,450 unvested restricted stock units (RSUs) with various vesting schedules: 29,922 RSUs granted March 8, 2025, vesting through March 8, 2028; 22,798 RSUs granted March 8, 2025, vesting through March 8, 2027; 14,474 RSUs granted March 8, 2024, vesting through March 8, 2027; and 7,256 RSUs granted March 8, 2023, vesting through March 8, 2026.

Sentiment

Score: 5

Explanation: The sale was conducted under a pre-arranged 10b5-1 plan, which typically indicates a scheduled liquidity event for personal financial planning rather than a reaction to new, undisclosed information. The amount sold is a small fraction of total holdings, leading to a neutral sentiment.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, which indicates a scheduled liquidity event rather than a discretionary sale based on new, undisclosed negative information.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived by the market as a slight reduction in an executive's direct equity exposure.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The shares set forth above were sold pursuant to the 10b5-1 Plan.

Industry Context

This Form 4 filing is a routine disclosure of an insider stock transaction and does not provide information relevant to broader industry trends or competitive dynamics within the medical device or continuous glucose monitoring sector.

Stakeholder Impact

• Shareholders: The impact on shareholders is minimal as this is a routine, pre-planned insider sale and does not suggest a change in company fundamentals. The small volume relative to total shares outstanding is unlikely to significantly affect market perception.

Next Steps

• Continued vesting of Sadie Stern's unvested restricted stock units according to their respective schedules through March 8, 2028.

Key Dates

Recommendation

The filing is a routine Form 4 disclosing an insider stock sale executed under a pre-arranged 10b5-1 plan. Such sales are typically for personal financial planning and do not usually signal a change in the company's fundamental outlook or warrant a change in investment recommendation based solely on this disclosure. Therefore, a 'hold' recommendation is appropriate as this filing does not provide new information to alter an existing investment thesis.

Keywords

Dexcom, DXCM, Insider Trading, Form 4, Stock Sale, Executive Compensation, 10b5-1 Plan, Restricted Stock Units